Company news

Alector, Inc. news in 2026

Alector, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Alector Announces Pricing of Underwritten Offering

October 16, 2026

Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline

October 7, 2026

Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases

October 5, 2026

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

May 7, 2026

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis

April 29, 2026

Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 25, 2026

Alector to Participate in the TD Cowen 46th Annual Health Care Conference

February 23, 2026

Decks in 2026